Premium
Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: II. Therapies for allergic bronchopulmonary aspergillosis
Author(s) -
Epps Quovadis J.,
Epps Kevin L.,
Zobell Jeffery T.,
Young David C.
Publication year - 2020
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.25080
Subject(s) - allergic bronchopulmonary aspergillosis , medicine , itraconazole , cystic fibrosis , voriconazole , omalizumab , posaconazole , tolerability , aspergillosis , azole , dermatology , intensive care medicine , immunology , immunoglobulin e , antifungal , antibody , adverse effect
This review is the second article in the State‐of‐the‐Art series and aims to evaluate medications used in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in pediatric and adult patients with cystic fibrosis (CF). ABPA is one of several organisms that are found in the airways of CF patients. This review provides an evidence‐based summary of pharmacokinetic (PK)/pharmacodynamic (PD), tolerability, and efficacy studies of medications including corticosteroids, amphotericin B, azole antifungals (isavuconazole, itraconazole, posaconazole, and voriconazole), and a monoclonal antibody omalizumab in the treatment of ABPA and identifies areas where further study is warranted.